Filana Therapeutics, Inc. Operating Lease, Payments
Filana Therapeutics, Inc. (FLNA) reported Operating Lease, Payments of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2024-05-10
- Filana Therapeutics, Inc. operating lease, payments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. operating lease, payments for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. operating lease, payments for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. operating lease, payments for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. operating lease, payments for fiscal 2023 was $24.00K, a 84.52% decline from fiscal 2022.
- Filana Therapeutics, Inc. operating lease, payments for fiscal 2022 was $155.00K, a 42.20% increase from fiscal 2021.
- Filana Therapeutics, Inc. operating lease, payments for fiscal 2021 was $109.00K, a 10.10% increase from fiscal 2020.
- Filana Therapeutics, Inc. operating lease, payments for fiscal 2020 was $99.00K, a 4.21% increase from fiscal 2019.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-05-10 | $0.00 derived: sum of 3 quarters · filed 2024-05-10 | $0.00 derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $24.00K 10-K · filed 2024-02-28 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $24.00K 10-Q · filed 2023-11-07 | $55.00K derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $24.00K 10-Q · filed 2023-08-03 | $55.00K derived: sum of 3 quarters · filed 2024-05-10 | $96.00K derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-03-31 | $24.00K 10-Q · filed 2024-05-10 | $55.00K derived: sum of 2 quarters · filed 2024-05-10 | $96.00K derived: sum of 3 quarters · filed 2024-05-10 | $137.00K derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $72.00K derived: sum of 2 quarters · filed 2024-02-28 | $113.00K derived: sum of 3 quarters · filed 2024-02-28 | $155.00K 10-K · filed 2024-02-28 | |
| 2022-09-30 | $41.00K 10-Q · filed 2023-11-07 | $42.00K 10-Q · filed 2022-11-07 | $82.00K derived: sum of 2 quarters · filed 2023-11-07 | $124.00K 10-Q · filed 2023-11-07 | $164.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $41.00K 10-Q · filed 2023-08-03 | $82.00K 10-Q · filed 2023-08-03 | $123.00K derived: sum of 3 quarters · filed 2024-02-28 | $164.00K derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $41.00K 10-Q · filed 2023-05-01 | $82.00K derived: sum of 2 quarters · filed 2024-02-28 | $123.00K derived: sum of 3 quarters · filed 2024-02-28 | $150.00K derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $82.00K derived: sum of 2 quarters · filed 2024-02-28 | $109.00K derived: sum of 3 quarters · filed 2024-02-28 | $109.00K 10-K · filed 2024-02-28 | |
| 2021-09-30 | $41.00K 10-Q · filed 2022-11-07 | $68.00K derived: sum of 2 quarters · filed 2022-11-07 | $68.00K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $27.00K 10-Q · filed 2022-08-04 | $27.00K 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $49.00K derived: sum of 2 quarters · filed 2023-02-28 | $74.00K derived: sum of 3 quarters · filed 2023-02-28 | $99.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $25.00K 10-Q · filed 2021-11-15 | $50.00K derived: sum of 2 quarters · filed 2021-11-15 | $75.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $25.00K 10-Q · filed 2021-08-04 | $50.00K 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $25.00K 10-Q · filed 2021-04-29 | ||||
| 2019-12-31 | $95.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |